



Epigenetics in Cancer and the Therapeutic Potential of Epi-Drugs

Guest Editors:

Dr. Sonia Emanuele

Dr. Antonietta Notaro

Dr. Adriana Cesesia

Deadline for manuscript
submissions:

closed (30 April 2024)

Message from the Guest Editors

Recent progresses in the field of epigenetics have clearly indicated that cancer cells not only display genetic mutations, but also epigenetic abnormalities, accounting for tumour development and progression. Therefore, global changes in the epigenetic topography could be considered a hallmark of cancer, and the modulation of epigenetic modifications could represent a strategy to selectively target tumour cells. It is not by chance that epigenetic compounds such as histone deacetylase (HDAC) inhibitors or DNA demethylating agents have been developed and used as antitumor drugs either in vitro or in vivo; some of these compounds have already entered clinical trials and showed a certain efficacy. The aim of this Special Issue is to focus on the molecular mechanisms of epigenetic regulation in cancer and to describe possible therapeutic approaches based on the use of epigenetic compounds. In addition, the Special Issue aims to provide the molecular characterization of the action mechanisms induced by epigenetic compounds, including HDAC inhibitors, demethylating agents or other drugs modulating the histone code or acting on nucleosome positioning.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)